Your session is about to expire
← Back to Search
Monoclonal Antibodies
OS2966 for Malignant Glioma
Phase 1
Waitlist Available
Research Sponsored by OncoSynergy, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group
Summary
This trial tests OS2966, a new antibody medicine, in adults with recurring or worsening high-grade brain tumors. The medicine is delivered directly to the tumor using a special technique to bypass the brain's protective barrier, aiming to stop cancer cells from growing and spreading.
Eligible Conditions
- Malignant Glioma
- Brain Tumor
- Glioblastoma
- Anaplastic Astrocytoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Optimal Biological Dose
Secondary study objectives
Spatial Distribution of OS2966 when delivered via CED
Tumor Response Rate
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Direct Infusion of OS2966Experimental Treatment2 Interventions
OS2966 will be directly infused into the brain tumor and surrounding tumor infiltrated brain via convection-enhanced delivery
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gadoteridol
2023
Completed Phase 3
~750
Find a Location
Who is running the clinical trial?
OncoSynergy, Inc.Lead Sponsor
Infuseon Therapeutics, Inc.Industry Sponsor
3 Previous Clinical Trials
12 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger